OABI

OmniAb, Inc. licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to identify optimal antibodies and other target-binding proteins for its partners’ drug development efforts. Central to the OmniAb platform, Biological Intelligence, powers the immune systems of its engineered transgenic animals to create optimized antibody candidates for human therapeutics. Its proprietary transgenic animals, including OmniRat, OmniChicken and OmniMouse are genetically modified to generate antibodies with human sequences to streamline the development of human therapeutic candidates. OmniFlic and OmniClic are fixed or common light-chain rats and chickens, designed to facilitate the discovery of bispecific antibodies. OmniTaur provides cow-inspired antibodies with unique structural characteristics for challenging targets.

Wall Street analysts forecast OABI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OABI is 6.00 USD with a low forecast of 3.00 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

OmniAb Inc revenue for the last quarter amounts to 2.24M USD, decreased -46.33 % YoY.

OmniAb Inc. EPS for the last quarter amounts to -0.14 USD, decreased -12.50 % YoY.

OmniAb Inc (OABI) has 114 emplpoyees as of December 16 2025.

Today OABI has the market capitalization of 292.23M USD.